Caro Roten

Dr. Caro Roten


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JGJoachim De Groote
Joachim De Groote
CRCaro Roten
Caro Roten
EFElizaveta Fomenko
Elizaveta Fomenko
PCPascal Coorevits
Pascal Coorevits
AHAndré Harth
André Harth
YDYves Depaepe
Yves Depaepe
Background/Objectives: Knee osteoarthritis (OA) is a major cause of pain and functional disability worldwide, leading to a growing interest in more durable and less invasive therapies. Micro-fragmented adipose tissue (MFAT) injections have emerged as a promising frontier in regenerative therapies using mesenchymal stem cells (MSCs). This study assessed the safety and effectiveness of MFAT injections for symptomatic knee OA while investigating the duration of treatment effects. Methods: This longitudinal study screened patients with symptomatic Kellgren-Lawrence (KL) grade II-IV knee OA who received single-dose MFAT injections. Outcomes were assessed using the Knee injury and Osteoarthritis Outcome Score (KOOS) subscales at baseline, 3, 6, and 12 months. A linear mixed effects model was performed to explore how age, BMI, sex, and OA severity influence outcomes. Results: Among 39 evaluable patients, mean baseline KOOS was 46.5 (SD 18.1). KOOS scores improved significantly across all subscales, peaking at six months and remaining higher than baseline at 12 months. Improvements exceeded clinically meaningful thresholds, including KL grades IV. Female patients reported significantly worse overall outcomes than male patients (p < 0.05). Minor self-limiting synovitis was reported in 18% of cases, and no severe adverse events were observed. Conclusions: MFAT infiltration may represent a safe, minimally invasive option to improve symptoms and delay surgery in patients with knee OA, including those with advanced disease. These findings highlight the potential role of MFAT as part of the treatment algorithm for knee OA, although strategies to sustain long-term benefits and confirmatory trials are needed.

12 April 2026 in HAND
Verified
Journal Article
Closed access
CRCaro Roten
Caro Roten
SHStien Hoskens
Stien Hoskens
KVKira Vande Voorde
Kira Vande Voorde
KRKjell Van Royen
Kjell Van Royen
ADArne Decramer
Arne Decramer
BVBert Vanmierlo
Bert Vanmierlo
Background: Advanced Dupuytren’s contracture of the little finger is challenging due to irreversible soft tissue shortening. Conventional options such as limited fasciectomy or dermofasciectomy often yield limited function and high recurrence. Shortening arthrodesis of the proximal interphalangeal joint is usually a salvage procedure; its role as primary treatment is underexplored. Methods: This prospective single-center study (2019-2024) included patients with severe (Tubiana stage III-IV) little finger contracture treated with primary proximo-distal interphalangeal arthrodesis (PDIP) plus limited fasciectomy. Outcomes ≥1 year postoperatively included metacarpophalangeal range of motion, grip strength, Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH), visual analog scale (VAS) pain, bone fusion, complications, and recurrence. Results: Twelve patients were included. The mean preoperative contracture was 148°. At follow-up, mean metacarpophalangeal flexion was 99°, and full adduction was restored in 9 of 12 cases. All achieved radiographic fusion, with 42% fused by 6 to 8 weeks and all by 12 weeks. Mean QuickDASH improved from 21 to 5 ( P = .004); median VAS pain decreased from 1 to 0 ( P = .09). Complications were limited to 1 superficial infection, 1 early recurrence, and 1 adjacent-digit contracture. Conclusions: Primary PDIP arthrodesis with limited fasciectomy is a safe, effective first-line option for advanced little finger Dupuytren’s contracture, providing reliable correction, solid fusion, and functional recovery in a single stage.